Pain-free walking distance (meters)
Diabetic
We observed an increase in the pain-free walking distance (PWD) from 445.70 ± 544.60 m to 800 ± 675.80 m in the auto-BM-MNC group, and from 37.14 ± 46.45 m to 400 ± 420.3 m in the allo-WJ-MSC group at month one after the cell administration. In contrast, PWD decreased from 28.33 ± 40.77 m to 15.56 ± 32.45 m in the placebo group. After three months of having administered the cell-based therapy, the PWD continued increasing in the auto-BM-MNC and allo-WJ-MSC groups (928.60 ± 769.70 m vs. 635.70 ± 539.10 m), compared to the placebo group, in which the distance decreased (15 ± 34.64 m).At month six, the PWD was 725 ± 644.90 m and 654.30 ± 530.20 m in auto-BM-MNC and allo-WJ-MSC groups, respectively; while was 13.75 ± 35.03 m in the placebo group.At the end of the follow-up, the PWD between the auto-BM-MNC and the allo-WJ-MSC groups was significantly higher than the placebo group (850 ± 1061 m vs. 306 ± 225 m vs. 3.75 ± 7.44 m, respectively) (Fig. Diabetic patients with CTLI showed drastically reduced pain-free walking after auto-BM-MNC or allo-WJ-MSC treatment. Pain-free walking distance diminished from the first month of treatment with auto-BM-MNC and allo-WJ-MSCs, unlike in the placebo group. Measurements are expressed as mean ± standard deviation. Significant differences between: placebo group versus auto-BM-MNC group (#) (